Yu.S. Prokofyeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yu.S. Prokofyeva has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- M. N. Sharov
Russian University of Medicine, Moscow, Russia
14 shared publications - Sergey A. Rachin
National Association of Experts in Comorbid Neurology, Moscow, Russia
10 shared publications - Ruzanna R. Parsamyan
Saratov State Medical University named after V.I. Razumovsky
9 shared publications - Andrey P. Rachin
National Association of Experts in Comorbid Neurology, Moscow, Russia
8 shared publications - Marina Yurievna Maksimova
Research Center of Neurology
4 shared publications - Irina V. Sarvilina
Medical Center “Novomeditsina
3 shared publications
Latest Publications
- 2 July 2025
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 23 (2)
Dysfunctional pelvic pain in women
Objective. To identify the clinical features of dysfunctional pelvic pain in women and to evaluate its impact on the quality of life. Material and methods. Chronic pelvic pain persists for at least six months. We evaluated 103 women with dysfunctional pelvic pain regarding: 1) pain — 11-point numerical rating measure scale (NRS-11) and Pain Catastrophizing Scale (PCS); 2) symptoms of central sensitization — the Fibromyalgia Impact Questionnaire Revised (FIQR); 3) sleep —the Pittsburgh Sleep Quality Index (PSQI); 4) anxiety and depression — the Hospital Anxiety and Depression Scale (HADS); 5) quality of life — the SF-36 questionnaire. Results. Mean NRS-11 and PCS scores were 7.4±1.9 and 27.5±10.6, respectively, FIQR score — 7.2±1.6. Severity of dysmenorrhea was 7.7±2.1 points, dyspareunia — 7.1±2.5 points. Sleep quality was poor in 93.2% women. HADS score 8-10 of anxiety and depression were observed in 64.1% and 58.3% of women, 11—21 points — in 3.9% and 25.2% women, respectively. Mean sleep quality according to PSQI was poor (6-21 points) in 93.2% women. The SF-36 questionnaire revealed low quality of life in women with dysfunctional pelvic pain. Conclusion. Dysfunctional pelvic pain in women negatively affects the life quality in all items.
- 2 July 2025
- Published by Media Sphere Publishing Group in Russian Journal of Pain
- Vol. 23 (2)
Dysfunctional pelvic pain in women
Objective. To identify the clinical features of dysfunctional pelvic pain in women and to evaluate its impact on the quality of life. Material and methods. Chronic pelvic pain persists for at least six months. We evaluated 103 women with dysfunctional pelvic pain regarding: 1) pain — 11-point numerical rating measure scale (NRS-11) and Pain Catastrophizing Scale (PCS); 2) symptoms of central sensitization — the Fibromyalgia Impact Questionnaire Revised (FIQR); 3) sleep —the Pittsburgh Sleep Quality Index (PSQI); 4) anxiety and depression — the Hospital Anxiety and Depression Scale (HADS); 5) quality of life — the SF-36 questionnaire. Results. Mean NRS-11 and PCS scores were 7.4±1.9 and 27.5±10.6, respectively, FIQR score — 7.2±1.6. Severity of dysmenorrhea was 7.7±2.1 points, dyspareunia — 7.1±2.5 points. Sleep quality was poor in 93.2% women. HADS score 8-10 of anxiety and depression were observed in 64.1% and 58.3% of women, 11—21 points — in 3.9% and 25.2% women, respectively. Mean sleep quality according to PSQI was poor (6-21 points) in 93.2% women. The SF-36 questionnaire revealed low quality of life in women with dysfunctional pelvic pain. Conclusion. Dysfunctional pelvic pain in women negatively affects the life quality in all items.
- 1 May 2025
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 2 (2)
Back Pain Phenotypes from the Perspective of the New D-TIMER Concept: From Clinical Heterogeneity to Personalised Therapy
Back pain is a global public health problem characterised by high prevalence, significant economic burden and substantial impact on quality of life. Despite progress in understanding the pathophysiological aspects in the formation of back pain, the development of effective treatments remains a challenge. The traditional approach, which considers back pain as a single disease, does not take into account its inherent clinical heterogeneity. Back pain phenotyping, based on the identification of subgroups of patients with common clinical characteristics, pathophysiological mechanisms and prognosis, represents a promising approach to personalised diagnosis and therapy. This article provides an overview of the current state of research on back pain phenotypes, highlighting different approaches to their identification. The new concept of D-TIMER phenotyping of back pain and the prospects for its use in the development of new diagnostic and therapeutic strategies are presented.
- 1 May 2025
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 2 (2)
Back Pain Phenotypes from the Perspective of the New D-TIMER Concept: From Clinical Heterogeneity to Personalised Therapy
Back pain is a global public health problem characterised by high prevalence, significant economic burden and substantial impact on quality of life. Despite progress in understanding the pathophysiological aspects in the formation of back pain, the development of effective treatments remains a challenge. The traditional approach, which considers back pain as a single disease, does not take into account its inherent clinical heterogeneity. Back pain phenotyping, based on the identification of subgroups of patients with common clinical characteristics, pathophysiological mechanisms and prognosis, represents a promising approach to personalised diagnosis and therapy. This article provides an overview of the current state of research on back pain phenotypes, highlighting different approaches to their identification. The new concept of D-TIMER phenotyping of back pain and the prospects for its use in the development of new diagnostic and therapeutic strategies are presented.
- 12 March 2025
- Published by Media Sphere Publishing Group in Russian Journal of Human Reproduction
- Vol. 31 (1)
Experience with the use of amitriptyline for chronic pelvic pain associated with endometriosis
Chronic pelvic pain is the most common symptom of endometriosis. Objective. To evaluate the effectiveness of amitriptyline for chronic pelvic pain associated with endometriosis. Material and methods. A comparative analysis of the results of examination and treatment of 60 women (18—45 years old) with a histologically verified diagnosis of endometriosis and suffering from chronic pelvic pain was carried out. Patients, depending on the treatment received, were divided into three groups: group 1 — 22 women who received dienogest 2 mg; group 2 — 20 women who received dienogest and an antidepressant; group 3 — 18 women who underwent only surgical treatment. Results. Against the background of the therapy, the severity of chronic pelvic pain in patients of group 2 who took amitriptyline decreased by 4 points according to VAS. Depression was absent in 19 (95%) patients of group 2, compared to 6 (27.3%) in group 1. The level of quality of life and sexual function in patients of group 2 by the end of 3 months of treatment was higher than in patients of groups 1 and 3. Conclusion. Amitriptyline has demonstrated effectiveness in relieving chronic pain in endometriosis
- 12 March 2025
- Published by Media Sphere Publishing Group in Russian Journal of Human Reproduction
- Vol. 31 (1)
Experience with the use of amitriptyline for chronic pelvic pain associated with endometriosis
Chronic pelvic pain is the most common symptom of endometriosis. Objective. To evaluate the effectiveness of amitriptyline for chronic pelvic pain associated with endometriosis. Material and methods. A comparative analysis of the results of examination and treatment of 60 women (18—45 years old) with a histologically verified diagnosis of endometriosis and suffering from chronic pelvic pain was carried out. Patients, depending on the treatment received, were divided into three groups: group 1 — 22 women who received dienogest 2 mg; group 2 — 20 women who received dienogest and an antidepressant; group 3 — 18 women who underwent only surgical treatment. Results. Against the background of the therapy, the severity of chronic pelvic pain in patients of group 2 who took amitriptyline decreased by 4 points according to VAS. Depression was absent in 19 (95%) patients of group 2, compared to 6 (27.3%) in group 1. The level of quality of life and sexual function in patients of group 2 by the end of 3 months of treatment was higher than in patients of groups 1 and 3. Conclusion. Amitriptyline has demonstrated effectiveness in relieving chronic pain in endometriosis
- 1 March 2025
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 2 (1)
The Role of Central Sensitization and Disinhibition in the Maintenance of Chronic Back Pain: Focus on Myorelaxants. A Review
Chronic back pain (CBP) is a significant medical and social problem due to the complex interaction of peripheral and central mechanisms. This article is devoted to the analysis of the role of central sensitization and disinhibition in the pathogenesis of CPS, as well as to the rationale for the use of myorelaxants in the complex therapy of this condition. Central sensitization, characterized by increased excitability of neurons of the central nervous system, plays a key role in chronicity of pain syndrome. It results from prolonged nociceptive impulses, leading to changes in synaptic transmission and neuronal plasticity. Disinhibition, a decrease in the activity of inhibitory neuronal circuits, exacerbates central sensitization, contributing to increased pain perception and pain spread beyond the original focus. Myorelaxants, acting at different levels of the nervous system, help to reduce local muscle spasm, decrease pain impulsation and attenuate central sensitization. However, the efficacy and safety of different myorelaxants in CPS vary. The combination of mirtazapine (an antidepressant with analgesic properties) and tizanidine (a centrally acting myorelaxant) represents a promising approach to the complex effect on chronic pain mechanisms, modulating both central sensitization and disinhibition.
- 1 March 2025
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 2 (1)
The Role of Central Sensitization and Disinhibition in the Maintenance of Chronic Back Pain: Focus on Myorelaxants. A Review
Chronic back pain (CBP) is a significant medical and social problem due to the complex interaction of peripheral and central mechanisms. This article is devoted to the analysis of the role of central sensitization and disinhibition in the pathogenesis of CPS, as well as to the rationale for the use of myorelaxants in the complex therapy of this condition. Central sensitization, characterized by increased excitability of neurons of the central nervous system, plays a key role in chronicity of pain syndrome. It results from prolonged nociceptive impulses, leading to changes in synaptic transmission and neuronal plasticity. Disinhibition, a decrease in the activity of inhibitory neuronal circuits, exacerbates central sensitization, contributing to increased pain perception and pain spread beyond the original focus. Myorelaxants, acting at different levels of the nervous system, help to reduce local muscle spasm, decrease pain impulsation and attenuate central sensitization. However, the efficacy and safety of different myorelaxants in CPS vary. The combination of mirtazapine (an antidepressant with analgesic properties) and tizanidine (a centrally acting myorelaxant) represents a promising approach to the complex effect on chronic pain mechanisms, modulating both central sensitization and disinhibition.
- 1 March 2025
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 2 (1)
CUPOINTS - a New Model of chronic Pelvic Pain. The Place of Negative Childhood Experiences in the Formation of Primary Chronic Pelvic Pain Syndrome: а Review
INTRODUCTION. For more than three decades, researchers have studied the relationship between the presence of chronic pain conditions and adverse childhood experiences (NCE) such as sexual abuse and family troubles. A number of intermittent hypotheses have been put forward to explain the relationship between chronic pain and the presence of adverse childhood care, mainly focusing on concepts of biological rooting. The (NCE) has been called a public health crisis, and it is widely recognized that it has a detrimental impact on social consequences and health conditions. AIM. To conduct a meta-analysis of the scientific evidence and to identify the place of negative childhood experiences in the in the development of primary chronic pelvic pain syndrome. MATERIALS AND METHODS. We performed meta-analyses on this topic in the following databases: PubMed, Research Gate, Elsevier in the time frame from 2015 to 2024. The following phrases were used to search for suitable literature: "chronic pelvic pain", "adverse childhood experience", "chronic pelvic pain syndrome", "endometriosis", "upoint", "upoints". DISCUSSION. Chronic pelvic pain syndrome is a rather ambiguous and multicomponent disease that includes a variety of pathophysiological mechanisms, and, unfortunately, currently the leading mechanism for the development of this syndrome has not been identified. The diagnosis of CFS is a diagnosis of exclusion, in which there is no infectious and/or organic pathology in the pelvic organs. However, in order to arrive at this diagnosis, it is necessary to undergo various examinations by doctors of various specialties: urologist, gynecologist, gastroenterologist, neurologist, psychotherapist, etc. An important component in the diagnosis of CFS and the development of further treatment tactics is the UPOINT(S) phenotyping model, which includes 7 domains: Urinary, Psychosocial, Organ specific, Infectious, Neurological/systemic and musculospastic skeletal muscles), an assessment of sexual activity function. Recent research reports on the need to introduce an eighth domain called "negative childhood experiences" into this concept and modify this model from UPOINTS to CUPOINTS. CONCLUSION. In our opinion, negative childhood experiences are one of the key links in the chain of proper diagnosis and treatment of pelvic pain syndromes, since it has become obvious that negative childhood experiences have a huge impact on the formation of chronic pain in general and chronic pain in particular.
- 1 March 2025
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 2 (1)
CUPOINTS - a New Model of chronic Pelvic Pain. The Place of Negative Childhood Experiences in the Formation of Primary Chronic Pelvic Pain Syndrome: а Review
INTRODUCTION. For more than three decades, researchers have studied the relationship between the presence of chronic pain conditions and adverse childhood experiences (NCE) such as sexual abuse and family troubles. A number of intermittent hypotheses have been put forward to explain the relationship between chronic pain and the presence of adverse childhood care, mainly focusing on concepts of biological rooting. The (NCE) has been called a public health crisis, and it is widely recognized that it has a detrimental impact on social consequences and health conditions. AIM. To conduct a meta-analysis of the scientific evidence and to identify the place of negative childhood experiences in the in the development of primary chronic pelvic pain syndrome. MATERIALS AND METHODS. We performed meta-analyses on this topic in the following databases: PubMed, Research Gate, Elsevier in the time frame from 2015 to 2024. The following phrases were used to search for suitable literature: "chronic pelvic pain", "adverse childhood experience", "chronic pelvic pain syndrome", "endometriosis", "upoint", "upoints". DISCUSSION. Chronic pelvic pain syndrome is a rather ambiguous and multicomponent disease that includes a variety of pathophysiological mechanisms, and, unfortunately, currently the leading mechanism for the development of this syndrome has not been identified. The diagnosis of CFS is a diagnosis of exclusion, in which there is no infectious and/or organic pathology in the pelvic organs. However, in order to arrive at this diagnosis, it is necessary to undergo various examinations by doctors of various specialties: urologist, gynecologist, gastroenterologist, neurologist, psychotherapist, etc. An important component in the diagnosis of CFS and the development of further treatment tactics is the UPOINT(S) phenotyping model, which includes 7 domains: Urinary, Psychosocial, Organ specific, Infectious, Neurological/systemic and musculospastic skeletal muscles), an assessment of sexual activity function. Recent research reports on the need to introduce an eighth domain called "negative childhood experiences" into this concept and modify this model from UPOINTS to CUPOINTS. CONCLUSION. In our opinion, negative childhood experiences are one of the key links in the chain of proper diagnosis and treatment of pelvic pain syndromes, since it has become obvious that negative childhood experiences have a huge impact on the formation of chronic pain in general and chronic pain in particular.
- 1 March 2025
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 2 (1)
Somatovegetative Disorders in General Practice: an Algorithm for General Practitioners. A Review
Somatovegetative disorders (SVR) represent a significant clinical problem characterized by a variety of symptoms and difficulty in diagnosis in general medical practice. This article is devoted to a detailed analysis of modern approaches to the diagnosis and therapy of SVR, focusing on the optimization of patient management in primary care. The paper considers key aspects of differential diagnosis of SVR, including the exclusion of organic pathology and identification of comorbid anxiety disorders. The importance of a comprehensive approach is emphasized, including assessment of the patient's somatic and mental status, as well as the use of validated scales and questionnaires to quantify the severity of symptoms. Special attention is paid to the pharmacotherapy of SVR, in particular, first-line drugs used for the treatment of anxiety disorders. The efficacy and safety of different groups of drugs, including selective serotonin reuptake inhibitors (SSRIs), selective serotonin and norepinephrine reuptake inhibitors (SSRIs) and anxiolytics, are analyzed. In the context of pharmacotherapy of SVR the feasibility of etifoxine (Anxilera) is considered in detail. The mechanisms of action of the drug, its efficacy in the treatment of anxiety and vegetative symptoms, as well as its safety profile in comparison with other anxiolytics are discussed. The data of clinical studies confirming the efficacy and tolerability of etifoxine in the treatment of SVR are presented. In conclusion, the article presents an algorithm of SVR therapy for general practitioners, which includes the stages of choosing the optimal pharmacotherapy taking into account the evaluation of treatment efficacy. The necessity of an integrative approach combining pharmacotherapy with psychotherapeutic methods and lifestyle modification is emphasized. The algorithm is designed to optimize the management of patients with SVR in primary care and improve their quality of life.
- 1 March 2025
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 2 (1)
Somatovegetative Disorders in General Practice: an Algorithm for General Practitioners. A Review
Somatovegetative disorders (SVR) represent a significant clinical problem characterized by a variety of symptoms and difficulty in diagnosis in general medical practice. This article is devoted to a detailed analysis of modern approaches to the diagnosis and therapy of SVR, focusing on the optimization of patient management in primary care. The paper considers key aspects of differential diagnosis of SVR, including the exclusion of organic pathology and identification of comorbid anxiety disorders. The importance of a comprehensive approach is emphasized, including assessment of the patient's somatic and mental status, as well as the use of validated scales and questionnaires to quantify the severity of symptoms. Special attention is paid to the pharmacotherapy of SVR, in particular, first-line drugs used for the treatment of anxiety disorders. The efficacy and safety of different groups of drugs, including selective serotonin reuptake inhibitors (SSRIs), selective serotonin and norepinephrine reuptake inhibitors (SSRIs) and anxiolytics, are analyzed. In the context of pharmacotherapy of SVR the feasibility of etifoxine (Anxilera) is considered in detail. The mechanisms of action of the drug, its efficacy in the treatment of anxiety and vegetative symptoms, as well as its safety profile in comparison with other anxiolytics are discussed. The data of clinical studies confirming the efficacy and tolerability of etifoxine in the treatment of SVR are presented. In conclusion, the article presents an algorithm of SVR therapy for general practitioners, which includes the stages of choosing the optimal pharmacotherapy taking into account the evaluation of treatment efficacy. The necessity of an integrative approach combining pharmacotherapy with psychotherapeutic methods and lifestyle modification is emphasized. The algorithm is designed to optimize the management of patients with SVR in primary care and improve their quality of life.
- 1 September 2024
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 1 (3)
Diabetic Polyneuropathy: from Pathogenesis to Therapy and Prevention (to Help the General Practitioner)
Diabetes mellitus is a serious chronic disease that significantly impairs the quality of life of patients worldwide. It is also one of the top ten leading causes of adult mortality, with an estimated four million deaths worldwide in 2017 due to diabetes. The global prevalence of diabetes mellitus reached 9.3% (463 million people) in 2019 and is expected to increase to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045. The increasing prevalence of diabetes has led to an increased incidence of chronic diabetic complications. Diabetic peripheral neuropathies are frequently encountered as a common chronic complication of diabetes mellitus. This article reviews the etiology and pathogenesis of diabetic peripheral neuropathies, current diagnostic methods, and therapeutic approaches to treatment, including the role of acetylcholine and the efficacy of Ipidacrine (Neuromidine) in the therapy of this pathology. KEYWORDS: diabetes mellitus, diabetic polyneuropathy, Ipidacrine, Neuromidin
- 1 September 2024
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 1 (3)
Diabetic Polyneuropathy: from Pathogenesis to Therapy and Prevention (to Help the General Practitioner)
Diabetes mellitus is a serious chronic disease that significantly impairs the quality of life of patients worldwide. It is also one of the top ten leading causes of adult mortality, with an estimated four million deaths worldwide in 2017 due to diabetes. The global prevalence of diabetes mellitus reached 9.3% (463 million people) in 2019 and is expected to increase to 10.2% (578 million) by 2030 and 10.9% (700 million) by 2045. The increasing prevalence of diabetes has led to an increased incidence of chronic diabetic complications. Diabetic peripheral neuropathies are frequently encountered as a common chronic complication of diabetes mellitus. This article reviews the etiology and pathogenesis of diabetic peripheral neuropathies, current diagnostic methods, and therapeutic approaches to treatment, including the role of acetylcholine and the efficacy of Ipidacrine (Neuromidine) in the therapy of this pathology. KEYWORDS: diabetes mellitus, diabetic polyneuropathy, Ipidacrine, Neuromidin
- 1 September 2024
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 1 (3)
Chronic Back Pain: From Pathogenesis to Adequate Pharmacotherapy.
Chronic back pain is an actual problem of clinical medicine, the pathogenesis of which includes peripheral nociceptive stimulation, peripheral and/or central inflammation, abnormality of the central pain modulation network and mixed onset of various pathological mechanisms. Sources of nociceptive signal generation include the intervertebral disc, muscles, fasciae, facet joints, sacroiliac joints, pubic symphysis, ligaments and joint capsule, and other structures that contain nociceptors. Any event that causes tissue degeneration activates a massive inflammatory response that infiltrates the MPD, joints, muscles, fascia and other tissues, stimulates nociceptive receptors to produce inflammatory substances, which directly damages the nerve root and causes pain. Simultaneously, the damaged MPD and endplate stimulate pathological and invasive growth and proliferation of vessels and nerves in the MPD. Increasing evidence also suggests that systemic inflammation plays a crucial role in the pathogenesis of chronic back pain. The central mechanism of back pain involves altered sensory processing in the brain. Dysfunction of the descending pain modulation system results in amplification of pain information in the brain. Since monotherapy for chronic back pain is not optimal, it is necessary to promote the comprehensive treatment recommended by current international clinical guidelines and it is reasonable to combine several therapies to improve the clinical effect of therapy. The combination of Tizanidine and Mirtazapine is an effective pharmacotherapy for chronic back pain. KEYWORDS: Chronic back pain, pathogenesis of dorsalgia, Tizanidine, Mirtazapine
- 1 September 2024
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 1 (3)
Chronic Back Pain: From Pathogenesis to Adequate Pharmacotherapy.
Chronic back pain is an actual problem of clinical medicine, the pathogenesis of which includes peripheral nociceptive stimulation, peripheral and/or central inflammation, abnormality of the central pain modulation network and mixed onset of various pathological mechanisms. Sources of nociceptive signal generation include the intervertebral disc, muscles, fasciae, facet joints, sacroiliac joints, pubic symphysis, ligaments and joint capsule, and other structures that contain nociceptors. Any event that causes tissue degeneration activates a massive inflammatory response that infiltrates the MPD, joints, muscles, fascia and other tissues, stimulates nociceptive receptors to produce inflammatory substances, which directly damages the nerve root and causes pain. Simultaneously, the damaged MPD and endplate stimulate pathological and invasive growth and proliferation of vessels and nerves in the MPD. Increasing evidence also suggests that systemic inflammation plays a crucial role in the pathogenesis of chronic back pain. The central mechanism of back pain involves altered sensory processing in the brain. Dysfunction of the descending pain modulation system results in amplification of pain information in the brain. Since monotherapy for chronic back pain is not optimal, it is necessary to promote the comprehensive treatment recommended by current international clinical guidelines and it is reasonable to combine several therapies to improve the clinical effect of therapy. The combination of Tizanidine and Mirtazapine is an effective pharmacotherapy for chronic back pain. KEYWORDS: Chronic back pain, pathogenesis of dorsalgia, Tizanidine, Mirtazapine
- 1 March 2024
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 1 (1)
Functional Abdominal Pain Syndrome: A Review
INTRODUCTION. About 40–60% of adult patients with complaints of abdominal pain suffer from functional gastrointestinal disorders. Currently, functional disorders of the gastrointestinal tract are associated with disturbances in the gut-brain interaction. Abdominal pain syndrome can be one of the leading manifestations of irritable bowel syndrome, functional dyspepsia syndrome and abdominal migraine. The exclusion of organic disorders of the gastrointestinal tract is an essential condition for the diagnosis of functional disorders. The basic principles of the treatment of functional abdominal pain syndrome should be aimed at correcting the psychological disorders involved in the formation of pain sensation. MATERIAL AND METHODS. A review of the literature on this topic was conducted in the following databases: PubMed, Research Gate, Elsevier. The following phrases were used to search for literature: “Functional abdominal pain syndrome”, “Disorders of the gastrointestinal tract”. DISCUSSION. Functional abdominal pain syndrome is a rather complex and ambiguous disease, which is based on complex cerebroabdominal connections (direct and reverse). This diagnosis is an exception, in other words, the diagnosis takes place when there are no obvious organic causes of the disease. The diagnosis of the functional abdominal pain syndrome is long and complex and includes various instrumental and laboratory methods of examination. Various methods are used in the treatment of the functional abdominal pain syndrome, ranging from non-drug methods (cognitive behavioral therapy, hypnotherapy) and ending with the use of medicines (antidepressants). It is important to keep in mind that the diagnosis and treatment of the functional abdominal pain syndrome requires the active participation of doctors of different specialties who are able to build a personalized diagnostic and therapeutic route using a biopsychosociocultural approach. CONCLUSION. Functional abdominal pain syndrome attracts special attention in the diagnostic and therapeutic aspect. Although the exclusion of organic diseases is an essential condition for the diagnosis of the functional abdominal pain syndrome, it is necessary to take into account the connection and involvement of mental factors in the phenomenon of abdominal pain. Taking into account the complexity of the mechanisms involved in the development of functional gastrointestinal diseases, the basic principles of functional abdominal pain syndrome treatment should be aimed at correcting psychological disorders involved in the formation of pain sensation. KEYWORDS: functional abdominal pain syndrome, disturbances in the gut-brain interaction, interaction
- 1 March 2024
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 1 (1)
Functional Abdominal Pain Syndrome: A Review
INTRODUCTION. About 40–60% of adult patients with complaints of abdominal pain suffer from functional gastrointestinal disorders. Currently, functional disorders of the gastrointestinal tract are associated with disturbances in the gut-brain interaction. Abdominal pain syndrome can be one of the leading manifestations of irritable bowel syndrome, functional dyspepsia syndrome and abdominal migraine. The exclusion of organic disorders of the gastrointestinal tract is an essential condition for the diagnosis of functional disorders. The basic principles of the treatment of functional abdominal pain syndrome should be aimed at correcting the psychological disorders involved in the formation of pain sensation. MATERIAL AND METHODS. A review of the literature on this topic was conducted in the following databases: PubMed, Research Gate, Elsevier. The following phrases were used to search for literature: “Functional abdominal pain syndrome”, “Disorders of the gastrointestinal tract”. DISCUSSION. Functional abdominal pain syndrome is a rather complex and ambiguous disease, which is based on complex cerebroabdominal connections (direct and reverse). This diagnosis is an exception, in other words, the diagnosis takes place when there are no obvious organic causes of the disease. The diagnosis of the functional abdominal pain syndrome is long and complex and includes various instrumental and laboratory methods of examination. Various methods are used in the treatment of the functional abdominal pain syndrome, ranging from non-drug methods (cognitive behavioral therapy, hypnotherapy) and ending with the use of medicines (antidepressants). It is important to keep in mind that the diagnosis and treatment of the functional abdominal pain syndrome requires the active participation of doctors of different specialties who are able to build a personalized diagnostic and therapeutic route using a biopsychosociocultural approach. CONCLUSION. Functional abdominal pain syndrome attracts special attention in the diagnostic and therapeutic aspect. Although the exclusion of organic diseases is an essential condition for the diagnosis of the functional abdominal pain syndrome, it is necessary to take into account the connection and involvement of mental factors in the phenomenon of abdominal pain. Taking into account the complexity of the mechanisms involved in the development of functional gastrointestinal diseases, the basic principles of functional abdominal pain syndrome treatment should be aimed at correcting psychological disorders involved in the formation of pain sensation. KEYWORDS: functional abdominal pain syndrome, disturbances in the gut-brain interaction, interaction
- 1 March 2024
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 1 (1)
Diabetic Dorsopathy: from Theory to Practice
ABSRTACT INTRODUCTION. Currently, in the scientific literature, the problem of the relationship between pain in the lower back and diabetes mellitus is given great attention, and therefore the term diabetic dorsopathy has appeared. CONCLUSION. The treatment strategy for a patient with back pain depends on the age of presentation, the severity of disc degeneration associated with nerve compression, the stability of the functional spine, and the overall balance of the spinal column (ie, sagittal balance). Therapy for diabetic dorsopathy is based on the general principles of treating nonspecific back pain. The drugs of choice for acute back pain are non-steroidal anti-inflammatory drugs, when choosing which you need to take into account their pharmacodynamics and pharmacokinetics. Artoxan (tenoxicam) according to these parameters demonstrates proper efficiency and safety. In a patient with a polyneuropathic component of back pain and diabetic polyneuropathy, it is advisable to include the drug Cocarnit in complex therapy. The quadro-effect of Cocarnit components is able to influence different points of formation of complications of diabetes and significantly improve the quality of life of such patients, restoring neurometabolic processes, reducing pain, the drug increases patient adherence to therapy. KEYWORDS: comorbidity, pain, diabetes, diabetic dorsopathy
- 1 March 2024
- Published by MEDIKON LLC in Comorbidity neurology
- Vol. 1 (1)
Diabetic Dorsopathy: from Theory to Practice
ABSRTACT INTRODUCTION. Currently, in the scientific literature, the problem of the relationship between pain in the lower back and diabetes mellitus is given great attention, and therefore the term diabetic dorsopathy has appeared. CONCLUSION. The treatment strategy for a patient with back pain depends on the age of presentation, the severity of disc degeneration associated with nerve compression, the stability of the functional spine, and the overall balance of the spinal column (ie, sagittal balance). Therapy for diabetic dorsopathy is based on the general principles of treating nonspecific back pain. The drugs of choice for acute back pain are non-steroidal anti-inflammatory drugs, when choosing which you need to take into account their pharmacodynamics and pharmacokinetics. Artoxan (tenoxicam) according to these parameters demonstrates proper efficiency and safety. In a patient with a polyneuropathic component of back pain and diabetic polyneuropathy, it is advisable to include the drug Cocarnit in complex therapy. The quadro-effect of Cocarnit components is able to influence different points of formation of complications of diabetes and significantly improve the quality of life of such patients, restoring neurometabolic processes, reducing pain, the drug increases patient adherence to therapy. KEYWORDS: comorbidity, pain, diabetes, diabetic dorsopathy